Amazon has officially stepped deeper into the booming weight-loss drug market, launching a new GLP-1 treatment program designed to make obesity care faster, more convenient, and more accessible for patients.

Novo Nordisk announced Tuesday that its experimental obesity treatment UBT251, a triple agonist targeting the GLP-1, GIP and glucagon receptors, delivered a statistically significant mean weight loss of up to 19.7% after 24 weeks in a clinical trial.

Novo Nordisk said on Monday that its next-generation obesity treatment CagriSema proved less effective than tirzepatide, developed by Eli Lilly, in a head-to-head clinical trial — marking a setback in the competitive race for dominance in the fast-growing weight-loss drug market.